Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Memo To File: How US FDA Decided Which Janssen Vaccine Drug Substance Batches Were OK To Use

Executive Summary

Two batches were authorized because they were made before production waste jammed Emergent BioSolutions' Bayview plant.

You may also be interested in...



The Quality Lowdown: Enforcement And Compliance During A Lingering Pandemic

US FDA oversees plants straining to meet demand for COVID-19 vaccines and treatments, while cracking down on adulterated hand sanitizers.

Emergent COVID-19 Vaccine Plant’s Quality Issues Draw Unusual Spotlight From US FDA Topsiders

Remediation must be quick and sure, say FDA’s Woodcock and Marks, despite challenges with facilities, equipment, processes and personnel training.

Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant

After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel